Biodesix (BDSX) Stock
Blood diagnostics company for lung disease and cancer. Here's the price, business snapshot, and what's worth knowing about Biodesix in August 2026.
Biodesix, Inc (BDSX) is a US-based diagnostics company that develops blood‑based proteomic tests and data analytics for lung disease and oncology. Its products aim to help clinicians improve diagnostic accuracy and treatment decisions through machine‑learning enabled assays and commercial partnerships. With a market capitalisation of roughly $50 million, Biodesix is a small‑cap, early‑stage healthcare company, which typically brings higher volatility, lower liquidity and greater sensitivity to clinical, reimbursement and funding outcomes. Potential upside drivers include wider clinical adoption of its assays, favourable reimbursement decisions and collaborations with providers or pharmaceutical firms. Key risks include limited revenue scale, cash burn that may require future financing, regulatory or clinical setbacks, and competitive alternatives. This information is educational only and not investment advice; investors should assess their risk tolerance, review company filings and consult a financial adviser before considering any position.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Biodesix's stock, with a target price of $32.50, indicating strong potential growth.
Financial Health
Biodesix is performing well with strong revenue and cash flow, supported by impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Commercial adoption watch
Investors may watch test uptake and reimbursement; these drive revenue growth, though adoption can be slower than expected and affect results.
Technology and data
Proteomics plus machine learning underpin the offering and could differentiate products, but robust clinical validation is essential.
Partners and scale
Partnerships with hospitals and pharma can extend reach and credibility, yet competitive pressures and payment systems can limit impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.